Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up.

[1]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[2]  F. Kronenberg,et al.  The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. , 1999, Journal of the American Society of Nephrology : JASN.

[3]  F. Kronenberg,et al.  Influence of hematocrit on the measurement of lipoproteins demonstrated by the example of lipoprotein(a). , 1998, Kidney international.

[4]  T. Rabelink,et al.  Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. , 1998, Journal of the American Society of Nephrology : JASN.

[5]  F. Kronenberg.  Homocysteine, lipoprotein(a) and fibrinogen: metabolic risk factors for cardiovascular complications of chronic renal disease , 1998, Current opinion in nephrology and hypertension.

[6]  F. Kronenberg,et al.  Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. , 1997, Journal of the American Society of Nephrology : JASN.

[7]  F. Kronenberg,et al.  Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. , 1997, Journal of lipid research.

[8]  A. Oliveras,et al.  Effect of cyclosporine on serum lipoprotein(a) levels in renal transplant recipients. , 1997, Transplantation proceedings.

[9]  S. Fortmann,et al.  A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[10]  E. Doherty,et al.  The effect of change of renal replacement therapy on serum lipoprotein (a) concentration. , 1994, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[11]  L. Hunt,et al.  Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. , 1997, Nephron.

[12]  H. Hobbs,et al.  Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. , 1996, The Journal of clinical investigation.

[13]  K. Kostner,et al.  Urinary Excretion of Apo(a) Fragments: Role in Apo(a) Catabolism , 1996 .

[14]  V. Armstrong,et al.  Decrease in lipoprotein(a) after renal transplantation is related to the glucocorticoid dose , 1996, European journal of clinical investigation.

[15]  B. Kasiske,et al.  Post-transplant hyperlipidemia: mechanisms and management. , 1996, Journal of the American Society of Nephrology : JASN.

[16]  D. Wheeler,et al.  Factors influencing plasma lipid profiles including lipoprotein (a) concentrations in renal transplant recipients , 1996, Transplant international : official journal of the European Society for Organ Transplantation.

[17]  H. Hobbs,et al.  Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a). , 1996, The Journal of clinical investigation.

[18]  G. Utermann,et al.  The relative electrophoretic mobility of apo(a) isoforms depends on the gel system: proposal of a nomenclature for apo(a) phenotypes. , 1995, Atherosclerosis.

[19]  F. Kronenberg,et al.  Lipoprotein(a) in renal disease. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  F. Kronenberg,et al.  Lipoprotein(a) in health and disease. , 1996, Critical reviews in clinical laboratory sciences.

[21]  A. Tejani,et al.  Hyperlipidemia in children: the role of uremia, steroids and cyclosporine therapy. , 1996, Nephron.

[22]  P. McNamee,et al.  Effect of immunosuppressive drug regime on cardiovascular risk profile following kidney transplantation. , 1995, Atherosclerosis.

[23]  F. Kronenberg,et al.  Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. , 1995, Journal of the American Society of Nephrology : JASN.

[24]  D. Webb,et al.  Serial changes in blood pressure, renal function, endothelin and lipoprotein (a) during the first 9 days of cyclosporin therapy in males , 1995, Journal of hypertension.

[25]  A. Hoitsma,et al.  The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. , 1995, Journal of the American Society of Nephrology : JASN.

[26]  J. Chapman,et al.  Predicting glomerular filtration rate after simultaneous pancreas and kidney transplantation. , 1995, Clinical transplantation.

[27]  M. Seed,et al.  Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  W. Lye,et al.  Abnormal lipoprotein (a) and lipid profiles in renal allograft recipients: effects of treatment with pravastatin. , 1995, Transplantation proceedings.

[29]  M. Vilardell,et al.  Serum lipoprotein (a) levels in patients with chronic renal failure--evolution after renal transplantation and relationship with other parameters of lipoprotein metabolism: a prospective study. , 1995, Nephron.

[30]  M. H. Gault,et al.  Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature. , 1995, Nephron.

[31]  C. Wanner,et al.  Protein loss and genetic polymorphism of apolipoprotein(a) modulate serum lipoprotein(a) in CAPD patients. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  T. Ozben,et al.  Serum lipoproteins in renal transplant patients: the effect of cyclosporine on lipoprotein(a). , 1994, Transplantation proceedings.

[33]  E. Friedman,et al.  Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels in renal transplant recipients. Evidence for renal involvement in the maintenance of LDL-C and the elevation of Lp(a) concentrations in hemodialysis patients. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[34]  F. Kronenberg,et al.  Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[35]  M. Netea,et al.  High concentrations of lipoprotein(a) as a risk factor for coronary heart disease and hypertension in type II diabetic patients , 1994 .

[36]  F. Kronenberg,et al.  Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[37]  R. Omoto,et al.  Lipid and lipoprotein(a) in renal transplant recipients. , 1994, Transplantation proceedings.

[38]  F. Kronenberg,et al.  Effect of sample storage on the measurement of lipoprotein[a], apolipoproteins B and A-IV, total and high density lipoprotein cholesterol and triglycerides. , 1994, Journal of lipid research.

[39]  M. Yacoub,et al.  Does cyclosporin affect lipoprotein(a) concentrations? , 1994, The Lancet.

[40]  I. Khan,et al.  Antineutrophil cytoplasmic antibody associated vasculitis and renal failure in Behçet's disease. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  C. Yang,et al.  Serum levels of lipoprotein (a) after renal transplantation: short-term follow-up. , 1994, Nephron.

[42]  J. Feely,et al.  Lipoprotein(a) and treatment of chronic renal disease , 1993, Journal of internal medicine.

[43]  F. Kronenberg,et al.  Cyclosporin and serum lipids in renal transplant recipients , 1993, The Lancet.

[44]  F. Kronenberg,et al.  Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). , 1993, The Journal of clinical investigation.

[45]  R. Moore,et al.  Abnormal lipid and lipoprotein profiles following renal transplantation. , 1993, Transplantation proceedings.

[46]  M. Seed,et al.  Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients? , 1993, The Lancet.

[47]  L. Hunt,et al.  Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy. , 1993, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[48]  V. Sparacino,et al.  Lipoprotein (a) levels in end-stage renal failure and renal transplantation. , 1993, Nephron.

[49]  E. Boerwinkle,et al.  Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[50]  O. Faergeman,et al.  Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[51]  R. Heyka,et al.  Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Hemodialysis Patients , 1992, Circulation.

[52]  E. Boerwinkle,et al.  Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. , 1992, The Journal of clinical investigation.

[53]  J. Simons,et al.  Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation. , 1992, Australian and New Zealand journal of medicine.

[54]  D. Wilcken,et al.  Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. , 1992, Clinical chemistry.

[55]  P. McNamee,et al.  Apolipoprotein (a) concentration decreases following renal transplantation. , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[56]  E. Boerwinkle,et al.  Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. , 1991, The Journal of clinical investigation.

[57]  B Budowle,et al.  Fixed-bin analysis for statistical evaluation of continuous distributions of allelic data from VNTR loci, for use in forensic comparisons. , 1991, American journal of human genetics.

[58]  J. Thistlethwaite,et al.  Elevated lipoprotein(a) levels in renal transplantation and hemodialysis patients. , 1991, American journal of nephrology.

[59]  G. Appel,et al.  Lipid abnormalities in renal disease. , 1991, Kidney international.

[60]  Y. Bar-Khayim,et al.  Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels. , 1990, Kidney international.

[61]  G. Utermann,et al.  Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. , 1987, The Journal of clinical investigation.